Allan, L. M., Williams, J. H., Wellman, N. A., et al (1995) Effects of tobacco smoking, schizotypy and number of pre-exposures on latent inhibition in healthy subjects. Personality and Individual Differences, 19, 893–902.
Andreasan, N. C. (1987) The Comprehensive Assessment of Symptoms and History (CASH). Iowa City, IA: University of Iowa.
Baruch, I., Hemsley, D. R. & Gray, J. A. (1988) Differential performance of acute and chronic schizophrenics on a latent inhibition task. Journal of Nervous and Mental Disease, 176, 598–606.
Bazira, S. (1995) Psychotropic Drug Directory. Lundbeck Publication.
Bleuler, E. (1913) Dementia praecox or the group of schizophrenias. Translated into English in The Clinical Routes of the Schizophrenia Concept (eds Cutting, J. & Shephard, M.). Cambridge: Cambridge University Press.
Claridge, G. S. & Broks, R (1985) Schizotypy and hemisphere function. I: Theoretical considerations and measurement of schizotypy. Personality and Individual Differences, 5, 633–648.
Claridge, G. (ed.) (1997) Schizotypy: Implications for Illness and Health. Oxford: Oxford University Press.
Collect, D. (1994) Modelling Survival Data in Medical Research. London: Chapman & Hall.
Cox, D. R. & Oakes, D. (1984) Analysis of Survival Data. London: Chapman & Hall.
Dunn, L. A., Atwater, G. & Kilts, C. D. (1993) Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioural model of clinical drug action. Psychophormocology, 112. 315–323.
Eysenck, H. J. & Eysenck, S. B. G. (1975) Manual of the Eysenck Personality Questionnaire. London: Hodder & Stoughton.
Frith, C. D. (1992) The Cognitive Neuropsychology of Schizophrenia. Hove: Lawrence Erlbaum.
Ginton, A., Urca, G. & Lubow, R. E. (1975) The effects of preexposure to an unattended stimulus on subsequent learning: latent inhibition in adults. Bulletin of the Psychonomic Society, 5, 5–8.
Gray, J. A., Feldon, J., Rawlins, J. N. R., et al (1991) The neuropsychology of schizophrenia. Behaviour and Brain Sciences, 14, 1–84.
Gray, N. S., Hemsley, D. R. & Gray, J. A. (1992a) Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurology. Psychiatry and Brain Research, 1, 83–89.
Gray, N. S., Pickering, A. D., Hemsley, D. R., et al (1992) Abolition of latent inhibition by a single 5 mg dose of D-amphetamine in man. Psychophormocology, 107, 425–430.
Gray, N. S., Pilowsky, L. S., Gray, J. A., et al (1995) Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophrenia Research, 17, 95–107.
Guterman, Y., Joslassen, R. C., Bashore, T. E., et al (1996) Latent inhibition effects reflected in event-related brain potentials in healthy controls and schizophrenics. Schizophrenic Research, 20, 315–326.
Kapur, S., Remington, G., Jones, C, et al (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry, 153, 948–950.
Liddle, P. F. (1987) The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. British Journal of Psychiatry, 151, 145–151.
Lubow, R. E. (1989) Latent Inhibition and Conditioned
Attention Theory. Cambridge: Cambridge University Press.
Lubow, R. E., Weiner, I., Schlossberg, A., et al (1987) Latent inhibition and schizophrenia. Bulletin of the Psychonomic Society, 25, 464–467.
Lubow, R. E. & Gewlrtx, J. C. (1995) Latent inhibition in humans: data, theory and implications for schizophrenia. Psychotoglcol Bulletin, 117, 87–103.
Lukoff, D., Neuchterlein, K. H. & Ventura, J. (1986) Manual for Expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin, 12, 594–601.
Norusis, N. (1993) Advanced Statistics. Chicago, IL: SPSS Inc.
Swerdlow, N. R., Braff, D. L., Hartston, H., et al (1996) Latent inhibition in schizophrenia. Schizophrenia Research, 20, 91–103.
Walner, I., Israeli-Telerant, A. & Feldon, J. (1987) Latent inhibition is not affected by acute or chronic administration of 6 mg/kg dl-amphetamine. Psychopharmocology. 91. 345–351.
Williams, J. H., Wellman, N. A., Geaney, D. P., et al (1996) Antipsychotic drug effects in a model of schizophrenic attentional disorder: a randomised controlled trial of the effects of haloperidol on latent inhibition in healthy people, Biological Psychiatry, 40, 1135–1143.
Williams, J. H., Wellman, N. A., Geaney, D. P., et al (1997) Enhancement of latent inhibition by 1.0 mg intravenous haloperidol in two visual tasks: a randomised controlled trial in healthy people, Psychopharmocology, 133, 262–268.
Wolkin, A., Brodie, J. D., Barouche, F., et al (1989) Dopamine receptor occupancy and plasma haloperidol levels
Archives of General Psychiatry, 46, 482–483.
World Health Organization (1992) The ICD–10 Classficatin of Mental and Behavioural Disorders. Geneva: WHO
Yee, B. K., Feldon, J. & Rawlins, J. N. P. (1995) Latent inhibition in rats is abolished by NMDA-induced neuronal loss in the retrohippocampal region but this lesion effect can be prevented by systemic haloperidol treatment. Behavioral Neuroscience, 109, 227–240.